Kadans Science Partner welcomes CHARM Therapeutics to B900 at the Babraham Research Campus, Cambridge. CHARM Therapeutics is a 3D deep learning research company discovering and developing transformational medicines.
The facility will act as the new research & development (R&D) site for CHARM Therapeutics, providing the Company with the necessary capacity to support its growth plans as it continues to develop its transformational oncology pipeline.
Babraham Research Campus is an internationally recognized life sciences cluster, with over 60 companies and 2,000 employees co-located with the Babraham Institute providing shared facilities and supporting programs. The Campus is one of the UK’s leading places to support early-stage bioscience enterprises. World class research and business come together to promote innovation and strengthen links between academia and the commercial world, helping to discover new science and medicines of the future. Kadans works closely with the Babraham Research Campus team to help enhance and support the facilities and services on offer across the cluster.
Katie Nelson, Senior Asset Manager at Kadans Science Partner: “We are delighted to have CHARM Therapeutics join the thriving cluster of science & innovation businesses at the Babraham Research Campus. They are a great addition to the Campus and ecosystem of the area. They are a fantastic example of what Kadans can do working with our tenants to provide them best in class facilities.”
Sarah Skerratt, SVP, Head of Drug Discovery at Charm Therapeutics: ‘We are excited to announce that our Drug Discovery team will be relocating to the Babraham Research Campus. This move marks an important milestone for our organization as we continue to expand and advance our drug discovery programmes. We are grateful to Kadans for their collaboration and partnership in providing us with this exceptional facility. Their commitment to delivering high-quality space and amenities will undoubtedly help us to achieve our research and development objectives.’